Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Individuals with rosacea do not have an increased cardiovascular risk compared with controls, according to assessment with the Framingham risk score (FRS) and the systemic coronary risk evaluation (SCORE).
The correlation between SCORE levels and duration of rosacea does support the role played by inflammation in the pathogenesis of the skin disorder, according to the results of a recent case-control study conducted in Turkey and published in Atherosclerosis.
The investigators sought to determine the frequency of cardiovascular risk among individuals with rosacea vs controls through the use of FRS and SCORE levels. The current study was performed between January 2015 and November 2016.
A total of 85 patients with rosacea and 90 controls were enrolled in the study. Overall, 51.8% (44 of 85) of the participants with rosacea had the erythematotelangiectatic type and 48.2% (41 of 85) of the participants had the papulopustular type.
Mean FRS and SCORE levels did not differ significantly between the rosacea and control groups (P <.05). SCORE levels were significantly associated with the duration of rosacea (P =.034). Participants with the papulopustular type of rosacea did have a higher cardiovascular risk than did those with the erythematotelangiectatic type of rosacea (P >.05).
The investigators concluded that additional studies are warranted, including those involving individuals with the 4 subtypes of rosacea, to evaluate cardiovascular risk factors separately for each of the 4 disease subtypes.
Reference
Belli AA, Altun I. Assessment of Framingham risk score and systemic coronary risk evaluation in rosacea patients. Atherosclerosis. 2017;263:e193.
